CEU 2018 - Growth Hormone Deficiency: Diagnosis Challenges and Treatment Considerations
CEU 2018 - Growth Hormone Deficiency: Diagnosis Challenges and Treatment Considerations
Saturday, September 8, 2018 | Intercontinental Hotel Miami, Grand Ballroom | Program: 12:15 – 1:15 pm
This course is a live CME-certified Ancillary Symposium presented at Clinical Endocrinology Update (CEU 2018) East Coast meeting (September 6-8) held in Miami, FL. This educational activity is supported by an independent medical educational grant from Sandoz. These ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC).
PLEASE REGISTER THEN CLICK "START" TO:
EVALUATE THE SESSION
CLAIM CME
DOWNLOAD PRESENTATION SLIDES
PRINT A CERTIFICATE OF ATTENDANCE OR CERTIFICATE OF PARTICIPATION
Target Audience
This program will be of substantial interest to: endocrinologists and endocrine fellows, primary care and internal medicine physicians, physician’s assistants, nurse practitioners and other healthcare professionals caring for individuals with growth hormone deficiency.
Learning Objectives
- Incorporate up to date guideline recommendations when screening and testing for GHD
- Devise treatment strategies that incorporate current knowledge on the safety, risks, and benefits of long-term GH replacement in the management of GHD
- Apply diagnosis criteria and evaluate treatment options for patients with GHD management during the transition into adulthood
Additional Information
Program Chair
Shlomo Melmed, MD
Executive Vice President, Dean
Cedars-Sinai Medical Center
Los Angeles, California
Faculty
Craig Alter, MD
Professor of Clinical Pediatrics
Director, Neuroendocrine Center
Children's Hospital of Philadelphia
Perelman School of Medicine
Philadelphia, Pennsylvania
DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Shlomo Melmed, MD: Consultant: Cliasma, Midatech, Ionis. Primary Investigator (Research Grant): Pfizer, IPSEN.
Craig Alter, MD: Consultant: Opko.
The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships: Susmeeta Sharma, MD
The following SPC Committee members reported financial relationships:
Andrew Ahmann, MD: Research Support, DexCom, Lexicon, Medtronic, Novo Nordisk; Consultant, Dexcom, Eli Lilly & Company, Horizon CME, Mannkind, Novo Nordisk, Trividia Health, Sanofi; Speaker, Horizon CME
Giuseppe Barbesino, MD: Spouse, employee of Genzyme
Joan Han, MD: Research Support, Rhythm Pharmaceutical
Steven T. Harris, MD: Ad hoc consultant on Advisory Boards, Eli Lilly & Company, Merck, Radius Health; Speaker, Amgen, Eli Lilly & Company, Radius Health, Shire
Jonathan Purnell, MD: Advisor, Novo Nordisk
Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca /Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim
Neena Natt, MD: Member, Amgen Inc.
Amy Rothberg, MD: Spouse, employee of Merck; Data Safety Monitoring Board, Lexicon; Consultant, Johnson & Johnson
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
The following SPC members reported no relevant financial relationships:
Beret Ann Casey, MD; Lorena Alarcon-Casas Wright, MD
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

MAINTENANCE OF CERTIFICATION
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Review your Diplomate ABIM ID Number(s)
In order to earn and report MOC points to the American Board of Internal Medicine (ABIM), you must:
- Provide your board-certification information in your educational profile. Your profile currently contains the following board ID numbers (must be logged in to view):
Your ABIM Number: [current-user:profile-profile:field-number-abim]*
*If your ABIM number is blank or incorrect as shown above, please click the Update Profile button below to add or correct your profile.
Available Credit
- 1.00 ABIM MOC
- 1.00 AMA PRA Category 1 Credits™
- 1.00 CME Certificate of Participation